Red-Light District
Plan for Adult Area Sparks a Fight
On Control of Web

Dot-XXX Proposal Focuses
Global Ire on U.S. Role;
Is Regulator Independent?

Pressure From Conservatives

By Christopher Ricks

JUPITER, Fla. - Stuart Lawley wants to create a new Internet neighborhood for the adult-entertainment industry: dot-xxx. The 45-year-old British entre-

preneur believes the new three-letter ending for Web site addresses would help protect children from online por-

ography, by making it easier to filter such material. He also hopes to make a pile of money by collecting fees for regis-
ting dot-xxx sites.

The matter, which could be voted on as early as today by the organization that governs domain names, has triggered a raucous global debate involving free-

dom-of-speech advocates, child-protec-
tion groups, adult-content providers, for-

government and conservative Christian groups.

Mr. Lawley's proposal also raises

thorny issues for the U.S. government, which funded the creation of the Internet and has long played a behind-the-scenes role in running it. As the Internet grows

as a place of business and a forum for exchanging ideas, some have argued

Address Book

<table>
<thead>
<tr>
<th>Domain</th>
<th>Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>com</td>
<td>45,947,815</td>
</tr>
<tr>
<td>net</td>
<td>6,755,704</td>
</tr>
<tr>
<td>org</td>
<td>4,149,482</td>
</tr>
<tr>
<td>info</td>
<td>2,389,925</td>
</tr>
<tr>
<td>biz</td>
<td>1,290,720</td>
</tr>
<tr>
<td>name</td>
<td>300,062</td>
</tr>
<tr>
<td>museum</td>
<td>16,162</td>
</tr>
</tbody>
</table>

* Estimate: Data from September 2005

Source: Zephyr.com

World-Wide

Katherine Harris
 Battles Old Friends
 For Florida's Keys

Despite Role in 2000 Recount,
Her Senate Bid Is Souring;
Jeb Bush Speaks Bluntly

By John D. McKinnon

WATER PALM BEACH, Fla. - Katherine Harris, owner of the Florida recount that tipped the presidency to George W. Bush, is running for a U.S. Senate seat.

But instead of gracefully supporting her, the Republican establishment just wish she'd go away.

Democrats are having a field day with the candidate's entanglement in a Wash-

ington lobbying scandal as well as her maverick political touch - she once

made a speech about a terrorist plot that didn't exist. She's badly trau-
matic in becoming Bill Nelson in the polls. A slew of shaffers have quit her senatorial campaign, tapped by her management style.

Iraq's prime minister ex-


Once the aircraft was off, the

Last word, Advanced

Rumsfeld defended the nomi-

nated by the CIA and denied the

Pentagon's ongoing involvement.

light of Iraq intelligence failures.

A Gore-backed group intends to

universities and the government, once

lax about protecting this country's

property rights, have all become more

aggressive about clamping down on
discussions of national security.

An early spur to this shift was a 1996
law that allowed universities to retain

the rights to intellectual property devel-

oped with federal research. Patent

scientists created a new law that

brought more money into university

research.

Dr. Crabtree and his research col-

leagues, who were the ones who
discovered the Protein C gene, and that

Lilly left them off the patent

file.

The drug Lilly went on to develop is X-

igris, used for the blood thinning treat-

ment. It was a $250 million seller for

Lilly last year.

Lilly's contribution to the "dis-

covery" of Protein C, which is used in

anticoagulant therapy, was not recog-

nized in the patent filing.

The NIH has joined the legal fray,

siding with the two scientists against

Lilly. But the NIH disagrees with them

about what should get the bulk of

any royalties on Xigris. It says in court

filings that most royalties should go to

the university, since Drs. Crabtree and

Plutzik were working in NIH labs.

Lilly began focusing on Protein C in

the early 1980s after other scientists, not

employed by the company, had the

insight that the substance prevented clots

from forming in the blood. Lilly figured

that if it could isolate and clone the gene

responsible for producing this protein, it

might find a potential weapon against

some blood diseases.

The case offers a vivid look at how
drugs are now built on many overlapping

areas of scientific work, ranging from

identifying one or several genes that

affect a disease to developing a compound

and a mechanism to deliver it. Work in

all of these areas can be patented, mak-

ing the science of drug discovery all the

more complex and contentious.